{"id":"https://openalex.org/W2096899475","doi":"https://doi.org/10.1200/jco.2003.02.008","title":"Use of Positron Emission Tomography in Pharmacokinetic Studies to Investigate Therapeutic Advantage in a Phase I Study of 120-Hour Intravenous Infusion XR5000","display_name":"Use of Positron Emission Tomography in Pharmacokinetic Studies to Investigate Therapeutic Advantage in a Phase I Study of 120-Hour Intravenous Infusion XR5000","publication_year":2003,"publication_date":"2003-01-13","ids":{"openalex":"https://openalex.org/W2096899475","doi":"https://doi.org/10.1200/jco.2003.02.008","mag":"2096899475","pmid":"https://pubmed.ncbi.nlm.nih.gov/12525511"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2003.02.008","doi":"https://doi.org/10.1200/jco.2003.02.008","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2003.02.008","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5040991512","display_name":"DAVID J. PROPPER","orcid":"https://orcid.org/0000-0002-4274-5460","observed_orcids":["https://orcid.org/0000-0002-4274-5460"]},"institutions":[{"id":"https://openalex.org/I2800373718","display_name":"Beatson West of Scotland Cancer Centre","ror":"https://ror.org/03pp86w19","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2800373718"]},{"id":"https://openalex.org/I2801748203","display_name":"Hammersmith Hospital","ror":"https://ror.org/05jg8yp15","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I153355300","https://openalex.org/I2801748203"]},{"id":"https://openalex.org/I47508984","display_name":"Imperial College London","ror":"https://ror.org/041kmwe10","country_code":"GB","type":"education","lineage":["https://openalex.org/I47508984"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"D.J. Propper","raw_affiliation_strings":["From the CRC Department of Medical Oncology, Beatson Oncology Centre, Glasgow; and CRC PET Oncology Group, Division of Cancer Medicine, Imperial College School of Medicine, MRC Cyclotron Unit, Hammersmith Hospital, London, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the CRC Department of Medical Oncology, Beatson Oncology Centre, Glasgow; and CRC PET Oncology Group, Division of Cancer Medicine, Imperial College School of Medicine, MRC Cyclotron Unit, Hammersmith Hospital, London, UK","institution_ids":["https://openalex.org/I2800373718","https://openalex.org/I2801748203","https://openalex.org/I47508984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072378199","display_name":"Johann Sebastian De Bono","orcid":"https://orcid.org/0000-0002-2034-595X","observed_orcids":["https://orcid.org/0000-0002-2034-595X"]},"institutions":[{"id":"https://openalex.org/I2800373718","display_name":"Beatson West of Scotland Cancer Centre","ror":"https://ror.org/03pp86w19","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2800373718"]},{"id":"https://openalex.org/I2801748203","display_name":"Hammersmith Hospital","ror":"https://ror.org/05jg8yp15","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I153355300","https://openalex.org/I2801748203"]},{"id":"https://openalex.org/I47508984","display_name":"Imperial College London","ror":"https://ror.org/041kmwe10","country_code":"GB","type":"education","lineage":["https://openalex.org/I47508984"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"J. de Bono","raw_affiliation_strings":["From the CRC Department of Medical Oncology, Beatson Oncology Centre, Glasgow; and CRC PET Oncology Group, Division of Cancer Medicine, Imperial College School of Medicine, MRC Cyclotron Unit, Hammersmith Hospital, London, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the CRC Department of Medical Oncology, Beatson Oncology Centre, Glasgow; and CRC PET Oncology Group, Division of Cancer Medicine, Imperial College School of Medicine, MRC Cyclotron Unit, Hammersmith Hospital, London, UK","institution_ids":["https://openalex.org/I2800373718","https://openalex.org/I2801748203","https://openalex.org/I47508984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034832196","display_name":"Azeem Saleem","orcid":"https://orcid.org/0000-0002-5747-7577","observed_orcids":["https://orcid.org/0000-0002-5747-7577"]},"institutions":[{"id":"https://openalex.org/I2800373718","display_name":"Beatson West of Scotland Cancer Centre","ror":"https://ror.org/03pp86w19","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2800373718"]},{"id":"https://openalex.org/I2801748203","display_name":"Hammersmith Hospital","ror":"https://ror.org/05jg8yp15","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I153355300","https://openalex.org/I2801748203"]},{"id":"https://openalex.org/I47508984","display_name":"Imperial College London","ror":"https://ror.org/041kmwe10","country_code":"GB","type":"education","lineage":["https://openalex.org/I47508984"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"A. Saleem","raw_affiliation_strings":["From the CRC Department of Medical Oncology, Beatson Oncology Centre, Glasgow; and CRC PET Oncology Group, Division of Cancer Medicine, Imperial College School of Medicine, MRC Cyclotron Unit, Hammersmith Hospital, London, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the CRC Department of Medical Oncology, Beatson Oncology Centre, Glasgow; and CRC PET Oncology Group, Division of Cancer Medicine, Imperial College School of Medicine, MRC Cyclotron Unit, Hammersmith Hospital, London, UK","institution_ids":["https://openalex.org/I2800373718","https://openalex.org/I2801748203","https://openalex.org/I47508984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084653587","display_name":"Sian Ellard","orcid":"https://orcid.org/0000-0002-7620-5526","observed_orcids":["https://orcid.org/0000-0002-7620-5526"]},"institutions":[{"id":"https://openalex.org/I2800373718","display_name":"Beatson West of Scotland Cancer Centre","ror":"https://ror.org/03pp86w19","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2800373718"]},{"id":"https://openalex.org/I2801748203","display_name":"Hammersmith Hospital","ror":"https://ror.org/05jg8yp15","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I153355300","https://openalex.org/I2801748203"]},{"id":"https://openalex.org/I47508984","display_name":"Imperial College London","ror":"https://ror.org/041kmwe10","country_code":"GB","type":"education","lineage":["https://openalex.org/I47508984"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"S. Ellard","raw_affiliation_strings":["From the CRC Department of Medical Oncology, Beatson Oncology Centre, Glasgow; and CRC PET Oncology Group, Division of Cancer Medicine, Imperial College School of Medicine, MRC Cyclotron Unit, Hammersmith Hospital, London, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the CRC Department of Medical Oncology, Beatson Oncology Centre, Glasgow; and CRC PET Oncology Group, Division of Cancer Medicine, Imperial College School of Medicine, MRC Cyclotron Unit, Hammersmith Hospital, London, UK","institution_ids":["https://openalex.org/I2800373718","https://openalex.org/I2801748203","https://openalex.org/I47508984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032891503","display_name":"Eoin P. Flanagan","orcid":"https://orcid.org/0000-0002-6661-2910","observed_orcids":["https://orcid.org/0000-0002-6661-2910","https://orcid.org/0000-0003-1037-6338"]},"institutions":[{"id":"https://openalex.org/I2800373718","display_name":"Beatson West of Scotland Cancer Centre","ror":"https://ror.org/03pp86w19","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2800373718"]},{"id":"https://openalex.org/I2801748203","display_name":"Hammersmith Hospital","ror":"https://ror.org/05jg8yp15","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I153355300","https://openalex.org/I2801748203"]},{"id":"https://openalex.org/I47508984","display_name":"Imperial College London","ror":"https://ror.org/041kmwe10","country_code":"GB","type":"education","lineage":["https://openalex.org/I47508984"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"E. Flanagan","raw_affiliation_strings":["From the CRC Department of Medical Oncology, Beatson Oncology Centre, Glasgow; and CRC PET Oncology Group, Division of Cancer Medicine, Imperial College School of Medicine, MRC Cyclotron Unit, Hammersmith Hospital, London, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the CRC Department of Medical Oncology, Beatson Oncology Centre, Glasgow; and CRC PET Oncology Group, Division of Cancer Medicine, Imperial College School of Medicine, MRC Cyclotron Unit, Hammersmith Hospital, London, UK","institution_ids":["https://openalex.org/I2800373718","https://openalex.org/I2801748203","https://openalex.org/I47508984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034457278","display_name":"James Paul","orcid":"https://orcid.org/0000-0001-7367-5816","observed_orcids":["https://orcid.org/0000-0001-7367-5816"]},"institutions":[{"id":"https://openalex.org/I2800373718","display_name":"Beatson West of Scotland Cancer Centre","ror":"https://ror.org/03pp86w19","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2800373718"]},{"id":"https://openalex.org/I2801748203","display_name":"Hammersmith Hospital","ror":"https://ror.org/05jg8yp15","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I153355300","https://openalex.org/I2801748203"]},{"id":"https://openalex.org/I47508984","display_name":"Imperial College London","ror":"https://ror.org/041kmwe10","country_code":"GB","type":"education","lineage":["https://openalex.org/I47508984"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"J. Paul","raw_affiliation_strings":["From the CRC Department of Medical Oncology, Beatson Oncology Centre, Glasgow; and CRC PET Oncology Group, Division of Cancer Medicine, Imperial College School of Medicine, MRC Cyclotron Unit, Hammersmith Hospital, London, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the CRC Department of Medical Oncology, Beatson Oncology Centre, Glasgow; and CRC PET Oncology Group, Division of Cancer Medicine, Imperial College School of Medicine, MRC Cyclotron Unit, Hammersmith Hospital, London, UK","institution_ids":["https://openalex.org/I2800373718","https://openalex.org/I2801748203","https://openalex.org/I47508984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059799734","display_name":"Trivadi Sundaram Ganesan","orcid":"https://orcid.org/0000-0002-4671-8099","observed_orcids":["https://orcid.org/0000-0002-4671-8099"]},"institutions":[{"id":"https://openalex.org/I2800373718","display_name":"Beatson West of Scotland Cancer Centre","ror":"https://ror.org/03pp86w19","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2800373718"]},{"id":"https://openalex.org/I2801748203","display_name":"Hammersmith Hospital","ror":"https://ror.org/05jg8yp15","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I153355300","https://openalex.org/I2801748203"]},{"id":"https://openalex.org/I47508984","display_name":"Imperial College London","ror":"https://ror.org/041kmwe10","country_code":"GB","type":"education","lineage":["https://openalex.org/I47508984"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"T.S. Ganesan","raw_affiliation_strings":["From the CRC Department of Medical Oncology, Beatson Oncology Centre, Glasgow; and CRC PET Oncology Group, Division of Cancer Medicine, Imperial College School of Medicine, MRC Cyclotron Unit, Hammersmith Hospital, London, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the CRC Department of Medical Oncology, Beatson Oncology Centre, Glasgow; and CRC PET Oncology Group, Division of Cancer Medicine, Imperial College School of Medicine, MRC Cyclotron Unit, Hammersmith Hospital, London, UK","institution_ids":["https://openalex.org/I2800373718","https://openalex.org/I2801748203","https://openalex.org/I47508984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110067223","display_name":"D C Talbot","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2800373718","display_name":"Beatson West of Scotland Cancer Centre","ror":"https://ror.org/03pp86w19","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2800373718"]},{"id":"https://openalex.org/I2801748203","display_name":"Hammersmith Hospital","ror":"https://ror.org/05jg8yp15","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I153355300","https://openalex.org/I2801748203"]},{"id":"https://openalex.org/I47508984","display_name":"Imperial College London","ror":"https://ror.org/041kmwe10","country_code":"GB","type":"education","lineage":["https://openalex.org/I47508984"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"D.C. Talbot","raw_affiliation_strings":["From the CRC Department of Medical Oncology, Beatson Oncology Centre, Glasgow; and CRC PET Oncology Group, Division of Cancer Medicine, Imperial College School of Medicine, MRC Cyclotron Unit, Hammersmith Hospital, London, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the CRC Department of Medical Oncology, Beatson Oncology Centre, Glasgow; and CRC PET Oncology Group, Division of Cancer Medicine, Imperial College School of Medicine, MRC Cyclotron Unit, Hammersmith Hospital, London, UK","institution_ids":["https://openalex.org/I2800373718","https://openalex.org/I2801748203","https://openalex.org/I47508984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090126935","display_name":"Eric Ofori Aboagye","orcid":"https://orcid.org/0000-0003-2276-6771","observed_orcids":["https://orcid.org/0000-0003-2276-6771"]},"institutions":[{"id":"https://openalex.org/I2800373718","display_name":"Beatson West of Scotland Cancer Centre","ror":"https://ror.org/03pp86w19","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2800373718"]},{"id":"https://openalex.org/I2801748203","display_name":"Hammersmith Hospital","ror":"https://ror.org/05jg8yp15","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I153355300","https://openalex.org/I2801748203"]},{"id":"https://openalex.org/I47508984","display_name":"Imperial College London","ror":"https://ror.org/041kmwe10","country_code":"GB","type":"education","lineage":["https://openalex.org/I47508984"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"E.O. Aboagye","raw_affiliation_strings":["From the CRC Department of Medical Oncology, Beatson Oncology Centre, Glasgow; and CRC PET Oncology Group, Division of Cancer Medicine, Imperial College School of Medicine, MRC Cyclotron Unit, Hammersmith Hospital, London, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the CRC Department of Medical Oncology, Beatson Oncology Centre, Glasgow; and CRC PET Oncology Group, Division of Cancer Medicine, Imperial College School of Medicine, MRC Cyclotron Unit, Hammersmith Hospital, London, UK","institution_ids":["https://openalex.org/I2800373718","https://openalex.org/I2801748203","https://openalex.org/I47508984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074007795","display_name":"Pat Price","orcid":"https://orcid.org/0000-0003-4709-3323","observed_orcids":["https://orcid.org/0000-0003-4709-3323"]},"institutions":[{"id":"https://openalex.org/I2800373718","display_name":"Beatson West of Scotland Cancer Centre","ror":"https://ror.org/03pp86w19","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2800373718"]},{"id":"https://openalex.org/I2801748203","display_name":"Hammersmith Hospital","ror":"https://ror.org/05jg8yp15","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I153355300","https://openalex.org/I2801748203"]},{"id":"https://openalex.org/I47508984","display_name":"Imperial College London","ror":"https://ror.org/041kmwe10","country_code":"GB","type":"education","lineage":["https://openalex.org/I47508984"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"P. Price","raw_affiliation_strings":["From the CRC Department of Medical Oncology, Beatson Oncology Centre, Glasgow; and CRC PET Oncology Group, Division of Cancer Medicine, Imperial College School of Medicine, MRC Cyclotron Unit, Hammersmith Hospital, London, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the CRC Department of Medical Oncology, Beatson Oncology Centre, Glasgow; and CRC PET Oncology Group, Division of Cancer Medicine, Imperial College School of Medicine, MRC Cyclotron Unit, Hammersmith Hospital, London, UK","institution_ids":["https://openalex.org/I2800373718","https://openalex.org/I2801748203","https://openalex.org/I47508984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079633934","display_name":"Adrian Llewellyn Harris","orcid":"https://orcid.org/0000-0003-1376-8409","observed_orcids":["https://orcid.org/0000-0003-1376-8409","https://orcid.org/0000-0002-5222-4765"]},"institutions":[{"id":"https://openalex.org/I2800373718","display_name":"Beatson West of Scotland Cancer Centre","ror":"https://ror.org/03pp86w19","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2800373718"]},{"id":"https://openalex.org/I2801748203","display_name":"Hammersmith Hospital","ror":"https://ror.org/05jg8yp15","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I153355300","https://openalex.org/I2801748203"]},{"id":"https://openalex.org/I47508984","display_name":"Imperial College London","ror":"https://ror.org/041kmwe10","country_code":"GB","type":"education","lineage":["https://openalex.org/I47508984"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"A.L. Harris","raw_affiliation_strings":["From the CRC Department of Medical Oncology, Beatson Oncology Centre, Glasgow; and CRC PET Oncology Group, Division of Cancer Medicine, Imperial College School of Medicine, MRC Cyclotron Unit, Hammersmith Hospital, London, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the CRC Department of Medical Oncology, Beatson Oncology Centre, Glasgow; and CRC PET Oncology Group, Division of Cancer Medicine, Imperial College School of Medicine, MRC Cyclotron Unit, Hammersmith Hospital, London, UK","institution_ids":["https://openalex.org/I2800373718","https://openalex.org/I2801748203","https://openalex.org/I47508984"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5021317857","display_name":"Chris J. Twelves","orcid":"https://orcid.org/0000-0002-1849-7153","observed_orcids":["https://orcid.org/0000-0002-1849-7153"]},"institutions":[{"id":"https://openalex.org/I2800373718","display_name":"Beatson West of Scotland Cancer Centre","ror":"https://ror.org/03pp86w19","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2800373718"]},{"id":"https://openalex.org/I2801748203","display_name":"Hammersmith Hospital","ror":"https://ror.org/05jg8yp15","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I153355300","https://openalex.org/I2801748203"]},{"id":"https://openalex.org/I47508984","display_name":"Imperial College London","ror":"https://ror.org/041kmwe10","country_code":"GB","type":"education","lineage":["https://openalex.org/I47508984"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"C. Twelves","raw_affiliation_strings":["From the CRC Department of Medical Oncology, Beatson Oncology Centre, Glasgow; and CRC PET Oncology Group, Division of Cancer Medicine, Imperial College School of Medicine, MRC Cyclotron Unit, Hammersmith Hospital, London, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the CRC Department of Medical Oncology, Beatson Oncology Centre, Glasgow; and CRC PET Oncology Group, Division of Cancer Medicine, Imperial College School of Medicine, MRC Cyclotron Unit, Hammersmith Hospital, London, UK","institution_ids":["https://openalex.org/I2800373718","https://openalex.org/I2801748203","https://openalex.org/I47508984"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":1.6091,"has_fulltext":false,"cited_by_count":33,"citation_normalized_percentile":{"value":0.82017982,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":97},"biblio":{"volume":"21","issue":"2","first_page":"203","last_page":"210"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11395","display_name":"Radiopharmaceutical Chemistry and Applications","score":0.000699999975040555,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10522","display_name":"Medical Imaging Techniques and Applications","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/continuous-infusion","display_name":"continuous infusion","score":0.4580000042915344},{"id":"https://openalex.org/keywords/carbon-11-radiolabeling","display_name":"carbon-11 radiolabeling","score":0.8619999885559082},{"id":"https://openalex.org/keywords/tumor-pharmacokinetics","display_name":"tumor pharmacokinetics","score":0.6710000038146973},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.8640000224113464},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.8450000286102295},{"id":"https://openalex.org/keywords/myelosuppression","display_name":"myelosuppression","score":0.7860000133514404}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8835254907608032},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.7670067548751831},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.621411919593811},{"id":"https://openalex.org/C2780852908","wikidata":"https://www.wikidata.org/wiki/Q127076","display_name":"Vomiting","level":2,"score":0.5222036242485046},{"id":"https://openalex.org/C2989005","wikidata":"https://www.wikidata.org/wiki/Q214963","display_name":"Nuclear medicine","level":1,"score":0.5028998255729675},{"id":"https://openalex.org/C2775842073","wikidata":"https://www.wikidata.org/wiki/Q208376","display_name":"Positron emission tomography","level":2,"score":0.4928312599658966},{"id":"https://openalex.org/C2780580376","wikidata":"https://www.wikidata.org/wiki/Q186889","display_name":"Nausea","level":2,"score":0.4150088429450989},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.33540913462638855},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.30034002661705017},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.2885597348213196},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.27246594429016113}],"mesh":[{"descriptor_ui":"D000166","descriptor_name":"Acridines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000166","descriptor_name":"Acridines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000166","descriptor_name":"Acridines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002250","descriptor_name":"Carbon Radioisotopes","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007262","descriptor_name":"Infusions, Intravenous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000000981","qualifier_name":"diagnostic imaging","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D014018","descriptor_name":"Tissue Distribution","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014055","descriptor_name":"Tomography, Emission-Computed","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019540","descriptor_name":"Area Under Curve","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020714","descriptor_name":"Maximum Tolerated Dose","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1200/jco.2003.02.008","doi":"https://doi.org/10.1200/jco.2003.02.008","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2003.02.008","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},{"id":"pmid:12525511","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/12525511","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","raw_type":"Clinical Trial"},{"id":"pmh:oai:pure.atira.dk:openaire_cris_publications/0453f7dc-0f3a-4428-96fc-042ed06e6944","doi":null,"is_oa":false,"landing_page_url":"https://research.manchester.ac.uk/en/publications/0453f7dc-0f3a-4428-96fc-042ed06e6944","pdf_url":null,"source":{"id":"https://openalex.org/S4306400662","display_name":"Research Explorer (The University of Manchester)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I28407311","host_organization_name":"University of Manchester","host_organization_lineage":["https://openalex.org/I28407311"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Propper, D J, De Bono, J, Saleem, A, Ellard, S, Flanagan, E, Paul, J, Ganesan, T S, Talbot, D C, Aboagye, E O, Price, P, Harris, A L & Twelves, C 2003, 'Use of positron emission tomography in pharmacokinetic studies to investigate therapeutic advantage in a phase I study of 120-hour intravenous infusion XR5000', Journal of Clinical Oncology, vol. 21, no. 2, pp. 203-210. https://doi.org/10.1200/JCO.2003.02.008","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9922999739646912,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":27,"referenced_works":["https://openalex.org/W1536620394","https://openalex.org/W1586111039","https://openalex.org/W1868383104","https://openalex.org/W1893187277","https://openalex.org/W1964639478","https://openalex.org/W1964978463","https://openalex.org/W1977642217","https://openalex.org/W1977764785","https://openalex.org/W1979501769","https://openalex.org/W1980782542","https://openalex.org/W1981715024","https://openalex.org/W1982698061","https://openalex.org/W1990573114","https://openalex.org/W1991042431","https://openalex.org/W1999849080","https://openalex.org/W2003226308","https://openalex.org/W2029744079","https://openalex.org/W2030820821","https://openalex.org/W2058537071","https://openalex.org/W2061163224","https://openalex.org/W2072271825","https://openalex.org/W2084155245","https://openalex.org/W2138725922","https://openalex.org/W2140149558","https://openalex.org/W2167805334","https://openalex.org/W2169456841","https://openalex.org/W2266585575"],"related_works":["https://openalex.org/W2084971869","https://openalex.org/W1982698061","https://openalex.org/W2069494336","https://openalex.org/W2080566980","https://openalex.org/W2125528679","https://openalex.org/W2021960861","https://openalex.org/W1774923611","https://openalex.org/W2243019099","https://openalex.org/W2589282204","https://openalex.org/W1982457488"],"abstract_inverted_index":{"PURPOSE:":[0],"XR5000":[1,14,28,83,208,236],"(N-[2-(dimethylamino)ethyl]acridine-4-carboxamide)":[2],"is":[3,241],"a":[4,22,57],"topoisomerase":[5],"I":[6,24],"and":[7,79,102,113,137,252],"II":[8,239],"inhibitor.":[9],"Because":[10],"the":[11,71,106,114,128,151,160,173,187,267],"cytotoxicity":[12],"of":[13,26,59,148,207,260],"increases":[15],"markedly":[16],"with":[17,41,213,247],"prolonged":[18],"exposure,":[19],"we":[20],"performed":[21],"phase":[23,238],"study":[25],"weekly":[27],"by":[29,164],"120-hour":[30],"continuous":[31],"infusion":[32,206],"over":[33],"3":[34],"weeks.":[35],"PATIENTS":[36],"AND":[37],"METHODS:":[38],"Twenty-four":[39],"patients":[40,63,126],"advanced":[42],"solid":[43],"cancer":[44],"were":[45,130,189,250],"treated":[46],"at":[47,70,127,266],"seven":[48],"dose":[49,73,234],"levels":[50],"(700":[51],"to":[52,75],"4,060":[53,110],"mg/m2/120":[54,111,118,243],"hrs)":[55],"for":[56,235],"total":[58],"67":[60],"cycles.":[61],"Three":[62],"underwent":[64],"positron":[65],"emission":[66],"tomography":[67],"(PET)":[68],"studies":[69,240,246],"maximum-tolerated":[72],"(MTD)":[74],"evaluate":[76],"normal":[77,183],"tissue":[78,184],"tumor":[80,224,261],"carbon-11":[81],"radiolabeled":[82],"([11C]XR5000)":[84],"pharmacokinetics.":[85],"RESULTS:":[86],"The":[87,232],"dose-limiting":[88],"toxicity":[89],"was":[90,116,143,179,202,227,263],"National":[91],"Cancer":[92],"Institute":[93],"Common":[94],"Toxicity":[95],"Criteria":[96],"(version":[97],"1)":[98],"grade":[99,121,140],"4":[100],"chest":[101],"abdominal":[103],"pain":[104],"affecting":[105,124],"single":[107,125],"patient":[108],"receiving":[109],"hours,":[112],"MTD":[115],"3,010":[117,242],"hours.":[119,244],"Other":[120],"3-4":[122],"toxicities,":[123],"MTD,":[129],"myelosuppression":[131],"(grade":[132],"4),":[133],"raised":[134],"bilirubin,":[135],"vomiting,":[136],"somnolence":[138],"(all":[139],"3).":[141],"There":[142],"one":[144],"partial":[145],"response":[146],"(adenocarcinoma":[147],"unknown":[149],"primary);":[150],"remainder":[152],"had":[153],"progressive":[154],"disease.":[155],"[11C]XR5000":[156,214],"distributed":[157],"well":[158],"into":[159,257],"three":[161],"tumors":[162,188],"studied":[163],"PET.":[165],"Tumor":[166,191],"uptake":[167],"(maximum":[168],"concentration":[169,174],"or":[170],"area":[171],"under":[172],"versus":[175],"time":[176],"curve":[177],"[AUC])":[178],"less":[180],"than":[181],"in":[182,185,197,237,254],"which":[186],"located.":[190],"exposure":[192,226,262],"(AUC;":[193],"mean":[194],"+/-":[195,210,218],"SD":[196],"m2/mL/sec)":[198],"increased":[199],"when":[200],"[(11)C]XR5000":[201],"administered":[203],"during":[204],"an":[205],"(0.242":[209],"0.4),":[211],"compared":[212],"given":[215],"alone":[216],"(0.209":[217],"0.04;":[219],"P":[220],"<.05),":[221],"indicating":[222],"that":[223],"drug":[225,249],"not":[228,264],"saturated":[229],"[corrected].":[230],"CONCLUSION:":[231],"recommended":[233],"PET":[245],"11C-labeled":[248],"feasible":[251],"demonstrated":[253],"vivo":[255],"distribution":[256],"tumors.":[258],"Saturation":[259],"reached":[265],"MTD.":[268]},"counts_by_year":[{"year":2020,"cited_by_count":1},{"year":2016,"cited_by_count":1},{"year":2014,"cited_by_count":3},{"year":2013,"cited_by_count":3}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}